Lisdexamfetamine

• Attention-deficit/hyperactivity disorder (ADHD)
• Binge eating disorder
• Treatment of ADHD in patients requiring long-acting stimulant
• Alternative when other stimulants cause problematic peaks and troughs

Lisdexamfetamine (Vyvanse) is a long-acting prodrug stimulant approved for attention-deficit hyperactivity disorder in patients six years and older and for moderate to severe binge eating disorder in adults. Because the molecule itself is inactive until the body converts it to dextroamphetamine, lisdexamfetamine produces a smoother concentration curve and lower abuse potential than immediate-release amphetamines. That pharmacology is the main reason it has become a workhorse for adult ADHD where steady, all-day symptom control matters more than a sharp peak. Many patients describe it as the most predictable stimulant they have used.

Mechanism of Action

Lisdexamfetamine is composed of dextroamphetamine covalently linked to the amino acid l-lysine. In this form it is pharmacologically inert and cannot stimulate the central nervous system. After oral absorption it travels through the portal circulation to red blood cells, where peptidase enzymes cleave the lysine and release dextroamphetamine into the bloodstream. The rate-limiting step is the enzymatic conversion rather than gastrointestinal absorption, which is why the resulting plasma curve looks more like an extended-release product than a quick-onset stimulant. Time to peak concentration is about three to four hours, and effective action persists for roughly 12 to 14 hours.

Dextroamphetamine itself raises synaptic concentrations of dopamine and norepinephrine in prefrontal cortex and striatum through several actions: it competitively inhibits the dopamine and norepinephrine reuptake transporters, reverses transporter direction so neurotransmitter is pushed back into the synapse, displaces monoamines from vesicular storage, and inhibits monoamine oxidase to a modest degree. The net effect on attention networks is improved signal-to-noise in cognitive control circuits, with measurable gains in sustained attention, working memory, and impulse control. Outside the CNS, peripheral noradrenergic effects raise heart rate and blood pressure modestly. The same mechanism that suppresses impulsive thoughts also reduces appetite, which is part of why the molecule works for binge eating disorder. The conversion-based design makes intranasal or intravenous misuse essentially ineffective, because the peptidase reaction does not occur in the nasal mucosa or directly in plasma at meaningful rates. Even when the capsule contents are dissolved and injected, the lack of red blood cell exposure renders the drug largely inactive at first pass. The NIMH ADHD overview provides additional background.

Clinical Use

For ADHD, current guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians position stimulants as first-line pharmacologic therapy in patients six and older when the diagnosis is well established and behavioral interventions alone are insufficient. Within stimulants, both amphetamine-based and methylphenidate-based products are reasonable starting points. Lisdexamfetamine competes with amphetamine-dextroamphetamine extended-release and with methylphenidate products such as Concerta and Quillivant. Compared with mixed amphetamine salts, lisdexamfetamine offers a flatter peak, less rebound in the late afternoon, and a smaller chance of misuse, which makes it appealing for adults, college students, and patients with prior substance concerns.

For binge eating disorder it is the only FDA-approved pharmacotherapy and is layered onto cognitive behavioral therapy rather than used in isolation. Patient selection considers cardiovascular history, sleep patterns, and prior response to stimulants. It is poorly suited to patients with structural heart disease, uncontrolled hypertension, severe anxiety disorders, untreated bipolar disorder, or active substance use disorders. Non-stimulant alternatives such as atomoxetine, viloxazine, guanfacine extended-release, or clonidine extended-release are reasonable when stimulants are contraindicated or poorly tolerated. Comparative effectiveness trials show stimulants outperform non-stimulants in symptom reduction, but non-stimulants have a place when sleep, appetite, or cardiac concerns dominate. Within the stimulant class itself, head-to-head data suggest roughly 70 percent of patients respond to any given stimulant on first trial, with response rates climbing toward 90 percent when patients are systematically tried on alternative agents after non-response. The American Academy of Family Physicians provides clinical practice references for primary care.

How to Take It

Lisdexamfetamine is taken once daily in the morning, with or without food. Morning dosing minimizes the insomnia that plagues afternoon or evening doses, since the drug provides roughly 12 to 14 hours of effect. The capsule can be swallowed whole or opened and dissolved completely in a glass of water, orange juice, or yogurt and consumed immediately. The chewable tablet is an alternative for patients who dislike capsules. Dose increases are made weekly in 10 to 20 mg steps until target benefit is reached or adverse effects limit further titration; typical adult ADHD doses fall between 30 and 70 mg, with 50 to 70 mg common for binge eating disorder. Missed morning doses should be taken if it is still early; afternoon catchups are usually skipped to protect sleep. Capsules and chewables are kept at room temperature in the original container. The first week often brings appetite suppression, dry mouth, and mild jitteriness; sleep and meal timing should be planned accordingly. Patients are encouraged to eat a substantial breakfast before the medication takes full effect and to keep nutrient-dense snacks handy for the rest of the day.

Monitoring and Follow-Up

Before starting, the clinician obtains a focused cardiovascular history, family history of sudden cardiac death, baseline blood pressure and pulse, height and weight, and a screen for psychiatric comorbidity including bipolar disorder. An EKG is not required for asymptomatic patients with normal exams but is performed if there is any cardiac concern. Follow-up at one month assesses symptom response with rating scales, blood pressure, pulse, weight, sleep, and appetite. Subsequent visits every three months in the first year and every six months thereafter recheck the same parameters. Heart rate increases above 20 bpm or systolic blood pressure rises above 10 to 15 mmHg from baseline warrant dose review. Persistent weight loss greater than 5 percent of body weight, growth velocity slowdown in children, or deteriorating sleep are other red numbers. Periodic medication holidays are sometimes used in children to confirm ongoing need and to allow growth catch-up. As a Schedule II controlled substance, lisdexamfetamine requires a new prescription each month and ongoing review of how the patient stores, uses, and tolerates the medication. Treatment agreements outlining safe storage and one-prescriber rules are common best practice. Periodic mood screening with PHQ-9 and GAD-7 helps detect emerging psychiatric concerns.

Special Populations

In children below age six the medication is not approved and other interventions are preferred. Adolescents and adults are the main treated populations. During pregnancy stimulants are associated with low birth weight and possible preterm birth; use during pregnancy is reserved for situations where benefits clearly outweigh risks. The drug enters breast milk, and breastfeeding is not generally recommended. In renal impairment with creatinine clearance below 30 mL/min the maximum dose is reduced to 50 mg; patients on dialysis are limited to 30 mg. Hepatic impairment requires caution but no fixed adjustment. Older adults rarely use stimulants, but when treated they require lower starting doses and closer cardiovascular monitoring. Patients with a personal or family history of substance use disorder need careful structured monitoring. Patients with a history of psychosis or bipolar disorder require psychiatric consultation before stimulant initiation because of the risk of triggering mania or psychotic symptoms. The FDA prescribing rules outline Schedule II requirements.

When to Contact Your Doctor

Call immediately for chest pain, shortness of breath, fainting, or new palpitations — these can signal a serious cardiovascular event. New paranoia, hallucinations, manic symptoms, or aggressive thoughts deserve urgent evaluation, particularly in the first month. Signs of circulation problems in fingers or toes such as numbness, color change, pain, or unexplained wounds may indicate Raynaud-type vasospasm. Severe insomnia, profound appetite suppression with weight loss, or growth concerns in children should prompt a dose review. Symptoms suggestive of serotonin syndrome — agitation, sweating, tremor, fever, diarrhea — when combined with serotonergic medications require immediate attention. Any seizure, severe headache, or loss of consciousness is an emergency. Persistent low mood, suicidal ideation, or any major personality change deserves urgent evaluation.

For evaluation of ADHD, binge eating disorder, or stimulant medication management coordinated with your overall health, contact us or schedule a visit at our St. Petersburg internal medicine practice for an integrated approach.